Department of Pathology, University of California, San Francisco, CA, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mod Pathol. 2014 Jan;27(1):55-61. doi: 10.1038/modpathol.2013.115. Epub 2013 Aug 9.
Synovial sarcoma and malignant peripheral nerve sheath tumor pose a significant diagnostic challenge given similar histomorphology. The distinction is further complicated by similar immunophenotype and especially by occasional synovial sarcomas that present as intraneural tumors. Although the presence of a t(X;18) rearrangement or expression of TLE1 can help confirm the diagnosis of synovial sarcoma, negative results for these tests are not diagnostic of malignant peripheral nerve sheath tumor. The SOX10 transcription factor, a putative marker of neural crest differentiation, may have diagnostic utility in this differential, but immunohistochemical data are limited. The goal of the present study was to determine the diagnostic utility of SOX10 to discriminate between synovial sarcoma and malignant peripheral nerve sheath tumor. Forty-eight cases of malignant peripheral nerve sheath tumor, all from patients with documented neurofibromatosis, and 97 cases of genetically confirmed synovial sarcoma, including 4 intraneural synovial sarcomas, were immunohistochemically stained for SOX10. The stain was scored for intensity and fraction of cells staining. Thirty-two of 48 malignant peripheral nerve sheath tumors (67%) were SOX10-positive. The majority of malignant peripheral nerve sheath tumors showed ≥2+ staining, but staining did not correlate with grade. By contrast, only 7/97 (7%) synovial sarcomas were SOX10-positive. Only three synovial sarcomas showed ≥2+ staining but, importantly, two of these were intraneural synovial sarcoma. Therefore, SOX10 is a specific (93%), albeit not very sensitive (67%), diagnostic marker to support a diagnosis of malignant peripheral nerve sheath tumor over synovial sarcoma. Furthermore, the stain needs to be interpreted with caution in intraneural tumors in order to avoid a potential diagnostic pitfall. It remains to be determined whether SOX10-positive cells in intraneural synovial sarcoma represent entrapped Schwann cells, synovial sarcoma cells or both.
滑膜肉瘤和恶性外周神经鞘瘤在组织形态学上相似,给诊断带来了很大的挑战。免疫表型相似,尤其是偶尔出现的表现为神经内肿瘤的滑膜肉瘤,使这一区别更加复杂。虽然存在 X;18 易位或 TLE1 表达有助于确认滑膜肉瘤的诊断,但这些检测结果阴性并不能诊断为恶性外周神经鞘瘤。SOX10 转录因子是神经嵴分化的假定标志物,在这种鉴别诊断中可能具有诊断效用,但免疫组化数据有限。本研究的目的是确定 SOX10 在区分滑膜肉瘤和恶性外周神经鞘瘤中的诊断效用。对 48 例有明确神经纤维瘤病的恶性外周神经鞘瘤和 97 例经基因证实的滑膜肉瘤(包括 4 例神经内滑膜肉瘤)进行 SOX10 免疫组化染色。对染色强度和染色细胞比例进行评分。48 例恶性外周神经鞘瘤中有 32 例(67%)SOX10 阳性。大多数恶性外周神经鞘瘤显示≥2+染色,但染色与分级无关。相比之下,只有 97 例滑膜肉瘤中的 7 例(7%)SOX10 阳性。只有 3 例滑膜肉瘤显示≥2+染色,但重要的是,其中 2 例为神经内滑膜肉瘤。因此,SOX10 是支持诊断恶性外周神经鞘瘤而非滑膜肉瘤的特异性(93%)标志物,但敏感性(67%)不高。此外,为了避免潜在的诊断陷阱,在神经内肿瘤中需要谨慎解读该染色。神经内滑膜肉瘤中的 SOX10 阳性细胞是否代表被困的施万细胞、滑膜肉瘤细胞还是两者都有,还有待确定。